Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Short Interest Update

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) saw a large increase in short interest in the month of December. As of December 31st, there was short interest totalling 1,720,000 shares, an increase of 13.2% from the December 15th total of 1,520,000 shares. Approximately 5.2% of the company’s shares are sold short. Based on an average daily volume of 773,000 shares, the short-interest ratio is presently 2.2 days.

Werewolf Therapeutics Stock Down 0.7 %

Shares of HOWL stock traded down $0.01 during midday trading on Friday, reaching $1.33. 179,090 shares of the stock were exchanged, compared to its average volume of 273,803. Werewolf Therapeutics has a 1 year low of $1.31 and a 1 year high of $8.19. The company’s 50 day moving average is $1.69 and its two-hundred day moving average is $2.09. The company has a current ratio of 10.10, a quick ratio of 10.10 and a debt-to-equity ratio of 0.29. The firm has a market cap of $59.26 million, a PE ratio of -0.87 and a beta of 0.38.

Institutional Trading of Werewolf Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in HOWL. Millennium Management LLC grew its stake in shares of Werewolf Therapeutics by 96.4% in the 2nd quarter. Millennium Management LLC now owns 1,110,298 shares of the company’s stock worth $2,709,000 after buying an additional 544,881 shares during the last quarter. PFM Health Sciences LP grew its stake in shares of Werewolf Therapeutics by 4.9% in the 3rd quarter. PFM Health Sciences LP now owns 3,398,747 shares of the company’s stock worth $7,205,000 after buying an additional 157,673 shares during the last quarter. Marshall Wace LLP grew its stake in shares of Werewolf Therapeutics by 410.5% in the 2nd quarter. Marshall Wace LLP now owns 134,184 shares of the company’s stock worth $327,000 after buying an additional 107,900 shares during the last quarter. Renaissance Technologies LLC grew its stake in shares of Werewolf Therapeutics by 103.1% in the 2nd quarter. Renaissance Technologies LLC now owns 171,000 shares of the company’s stock worth $417,000 after buying an additional 86,800 shares during the last quarter. Finally, Bank of New York Mellon Corp purchased a new stake in shares of Werewolf Therapeutics in the 2nd quarter worth approximately $165,000. Hedge funds and other institutional investors own 64.84% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the company. JMP Securities reduced their target price on Werewolf Therapeutics from $12.00 to $4.00 and set a “market outperform” rating on the stock in a report on Tuesday, January 14th. HC Wainwright reiterated a “buy” rating and set a $15.00 target price on shares of Werewolf Therapeutics in a report on Tuesday, November 19th.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.